Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPA-501 T Stem Cell Therapy for ALS
NCT04220190Phase 3Recruiting
- Sponsor
- Rapa Therapeutics
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of RAPA-501 in amyotrophic lateral sclerosis (ALS), sponsored by Rapa Therapeutics. Primary endpoint: Feasibility and safety of the highest established safe dose at 30 weeks. Started Jan 2025; status: recruiting.
02
Drugs
RAPA-501
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04220190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04220190.